Literature DB >> 15254416

p73 and p63: why do we still need them?

Giovanni Blandino1, Matthias Dobbelstein.   

Abstract

When p73 and p63 were initially described as homologues of the tumor suppressor p53, the three family members seemed almost exchangeable, raising the question why all three were retained during evolution. It later turned out that the corresponding genes, TP63 and TP73, appear phylogenetically older than TP53, and that their targeted deletion causes severe developmental defects, in contrast to a deletion of TP53. Hence, p63 and p73 are responsible for biological effects that cannot be elicited by p53 alone. Here, we provide an overview of properties ascribed to p63 and p73 that distinguish them from p53. Differences occur at the following levels: (i) protein structure, especially with regard to the aminoterminal transactivation domains and the carboxyterminal portions unique to p63 and p73; (ii) regulation, affecting mRNA levels, posttranslational modifications and interaction with other cellular proteins; (iii) activities, resulting in the regulation of gene expression, the programming of development, and the emergence of tumors. We speculate that, during the course of evolution, p63 and p73 have first pursued a broader range of activities, whereas p53 later specialized on genome maintenance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254416

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  Identification of mechanism that couples multisite phosphorylation of Yes-associated protein (YAP) with transcriptional coactivation and regulation of apoptosis.

Authors:  Kyung-Kwon Lee; Shin Yonehara
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

2.  Dipeptide analysis of p53 mutations and evolution of p53 family proteins.

Authors:  Qiang Huang; Long Yu; Arnold J Levine; Ruth Nussinov; Buyong Ma
Journal:  Biochim Biophys Acta       Date:  2013-04-10

3.  Human papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar.

Authors:  Ulziibat Shirendeb; Yoshitaka Hishikawa; Shingo Moriyama; Ne Win; Minn Minn Myint Thu; Khin Swe Mar; Gerlee Khatanbaatar; Hideaki Masuzaki; Takehiko Koji
Journal:  Acta Histochem Cytochem       Date:  2009-12-22       Impact factor: 1.938

Review 4.  Mechanisms, function and clinical applications of DNp73.

Authors:  Cuixia Di; Lina Yang; Hong Zhang; Xiaofei Ma; Xin Zhang; Chao Sun; Hongyan Li; Shuai Xu; Lizhe An; Xun Li; Zhongtian Bai
Journal:  Cell Cycle       Date:  2013-06-13       Impact factor: 4.534

5.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

6.  Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax.

Authors:  Seema Patel; Roger George; Flavia Autore; Franca Fraternali; John E Ladbury; Penka V Nikolova
Journal:  Nucleic Acids Res       Date:  2008-08-02       Impact factor: 16.971

7.  The alternative translated MDMX(p60) isoform regulates MDM2 activity.

Authors:  Anne-Sophie Tournillon; Ignacio López; Laurence Malbert-Colas; Nadia Naski; Vanesa Olivares-Illana; Robin Fåhraeus
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63.

Authors:  Barbara Testoni; Roberto Mantovani
Journal:  Nucleic Acids Res       Date:  2006-02-09       Impact factor: 16.971

Review 9.  Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Authors:  Maria Ferraiuolo; Silvia Di Agostino; Giovanni Blandino; Sabrina Strano
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

10.  Mathematical Modelling of Molecular Pathways Enabling Tumour Cell Invasion and Migration.

Authors:  David P A Cohen; Loredana Martignetti; Sylvie Robine; Emmanuel Barillot; Andrei Zinovyev; Laurence Calzone
Journal:  PLoS Comput Biol       Date:  2015-11-03       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.